MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based ...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALXO),, an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today ...

PENNINGTON, N.J. and SAN DIEGO, May 21, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer ...

RenovoRx will present its findings from a pharmacokinetic and pharmacodynamic sub-study of the Company’s ongoing Phase III TIGeR-PaC clinical trial, led by Dr. Paula Novelli of the University of ...

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are ...

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; ...

Real-world data from 844,000 patient records highlight the power of remote therapeutic monitoring to improve outcomes and reduce risk in chronic pain care The abstract presents a retrospective cohort ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters ...

KRAKOW, Poland, May 12, 2021 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU) today announced that three abstracts demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 ...

NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the ...

MARSEILLE, France--(BUSINESS WIRE)-- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today three abstracts including Innate’s product candidates have been ...